Analysts Are Bullish on Top Healthcare Stocks: ProMIS Neurosciences (PMN), Bruker (BRKR)

Globe and Mail

25-07-2025

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProMIS Neurosciences (PMN – Research Report) and Bruker (BRKR – Research Report) with bullish sentiments.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ProMIS Neurosciences (PMN)
In a report issued on July 21, Thomas Shrader from BTIG maintained a Buy rating on ProMIS Neurosciences, with a price target of $8.00. The company's shares closed last Thursday at $0.89, close to its 52-week low of $0.62.
According to TipRanks.com, Shrader is a 1-star analyst with an average return of -0.2% and a 35.4% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Coya Therapeutics, Inc., and Arcturus Therapeutics. ;'>
Currently, the analyst consensus on ProMIS Neurosciences is a Strong Buy with an average price target of $5.00, a 488.2% upside from current levels. In a report issued on July 14, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $4.00 price target.
Bruker (BRKR)
Leerink Partners analyst Puneet Souda maintained a Buy rating on Bruker on July 21 and set a price target of $65.00. The company's shares closed last Thursday at $40.27.
According to TipRanks.com, Souda 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.3% and a 30.5% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience. ;'>
Currently, the analyst consensus on Bruker is a Moderate Buy with an average price target of $52.33, a 31.3% upside from current levels. In a report issued on July 19, TR | OpenAI – 4o also upgraded the stock to Buy with a $45.00 price target.